Next Pharmaceuticals Signs Exclusive Supply Agreement With Kelatron For Its New Patented, Chromulin(TM)

Published: Jan 22, 2007

CARLSBAD, Calif.--(BUSINESS WIRE)--Next Pharmaceuticals announced today that it has signed an exclusive supply agreement with Kelatron for its patented Chromulin™ (U.S. Patent No. 6,689,383), an exciting breakthrough in chromium nutrition. Chromulin™ (chromium histidine) is water soluble and the most bio-available form of chromium, making it ideal for beverage applications and foods targeting any aspect of carbohydrate, protein, and fat metabolism.

Back to news